Bausch & Lomb eyes up VISX's payment and patent rights
This article was originally published in Clinica
Executive Summary
Bausch & Lomb is still not commenting on whether it plans to fall in line with VISX's payment per procedure strategy in the US or to challenge that company's patent position by not passing on fees when its Technolas 217 laser for LASIK procedures is launched at the end of the year. VISX at present claims a $250 fee per use for excimer laser photorefractive surgery procedures carried out in the US that are covered by one or more of its many patents in this area.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.